[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552350":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":29,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":29,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT","EXPERIMENTAL","Patients were treated by Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT",[13],"Drug: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients were treated by VA Conditioning Regimen Allo-HSCT:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg\u002Fm2 subcutaneous injection qd d1-7, donor stem cells infused from d9",[9],[20],"VA Conditioning Regimen Allo-HSCT",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066947192",null,"qlr2007@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":49,"phoneExt":29,"email":30},"Liren Qian, M.D.","+861066957676",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Liren Qian","Vice Director","100552350","phase-1-va-conditioning-regimen-allo-hsct-for-elderly-higher-risk-mds-100552350",false,"NCT06471946","VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS","Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.","ALL","70 Years",{"count":63,"type":64},54,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","The goal of this phase 1\u002F2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.",[71],"Higher-risk Myelodysplastic Syndromes","2024-09-28",{"date":74,"type":75},"2024-10-01","ACTUAL",{"date":74,"type":64},{"date":78,"type":64},"2030-09-01",{"name":5,"class":6},1]